Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia

Blood

Volumn 99, Issue 1, 2002, Pages 326-335

  Konopleva, Marina ^b   Tsao, Twee ^b   Ruvolo, Peter ^b   Stiouf, Irina ^b   Estrov, Zeev ^b   Leysath, Clinton E ^b   Zhao, Shourong ^b   Harris, David ^b   Chang, Shirong ^b   Jackson, C Ellen ^b   Munsell, Mark ^b   Suh, Nanjoo ^b   Gribble, Gordon ^b   Honda, Tadashi ^b   May, W Stratford ^b   Sporn, Michael B ^b   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DNA TOPOISOMERASE INHIBITOR; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAX; PROTEIN BCL 2; TRITERPENOID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL VIABILITY; COLONY FORMATION; DIMERIZATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

EID: 0036095959     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.326     Document Type: Article

References (73)

1. Acute myeloid leukemia
2. Treatment of relapsed and refractory acute myelogenous leukemia
3. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia
4. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995)
5. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients (pts) with acute myeloid leukemia (AML) <60 years old: Preliminary results of CALGB 9621
6. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± All-trans retinoic acid ± granulocyte-colony stimulating factor in poor prognosis newly diagnosed non-APLAML and MDS
7. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia
8. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells
9. Regulatory pathways in programmed cell death
10. Apoptosis: Molecules and mechanisms
11. Apoptosis regulating proteins as targets of therapy for hematological malignancies
12. Molecular thanatopsis: A discourse on the bcl2 family and cell death
13. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
14. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
15. Double identity for proteins of the Bcl-2 family
16. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis
17. Bcl-2 phosphorylation required for anti-apoptosis function
18. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis
19. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant bcl2 kinases
20. Bax and PKC alpha modulate the prognostic impact of Bcl-2 expression in acute myelogenous leukemia
21. Chemoprevention of cancer
22. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid
23. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds
24. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity
25. Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML
26. The novel triterpenoid 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism
27. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8-dependent mechanism
28. A synthetic triterpenoid, 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma
29. Synthetic oleanane and ursane triterpenoids with modified rings A and C: A series of highly active inhibitors of nitric oxide production in mouse macrophages
30. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)
31. Mechanisms of MDR in HL60 cells: Evidence that a surface membrane protein distinct from p-glycoprotein contributes to reduced cellular accumulation of drugs
32. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): Interactions with the macrocyclic lactone bryostatin 1
33. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA
34. A colony assay for proliferative blast cells circulating in myeloblastic leukemia
35. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation
36. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes
37. Immunohistochemical analysis of in vivo patterns of Bcl-X expression
38. Bcl-2 targets the protein kinase Raf-1 to mitochondria
39. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis
40. Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-α
41. Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia (CLL) and expression of apoptosis-regulating genes
42. A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V
43. Chloromethyl-X-rosamine is an aldehyde-fixable potential-sensitive fluorochrome for the detection of early apoptosis
44. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel
45. Mitochondrial permeability transition is a central coordinating event of apoptosis
46. Granzyme release and caspase activation in activated human T-lymphocytes
47. Requirement of the caspase-3/CPP32 protease cascade for apoptotic death following cytokine deprivation in hematopoietic cells
48. CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis
49. Conversion of bcl-2 to a Bax-like death effector by caspases
50. Bax directly induces release of cytochrome c from isolated mitochondria
51. N-terminal cleavage of bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death
52. The novel triterpenoid methyl-CDDO inhibits Bcl-2 phosphorylation and potently kills U937 cells
53. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
54. Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid
55. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression
56. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia
57. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia
58. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells
59. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis
60. Bax suppresses tumorigenesis and stimulates apoptosis in vivo
61. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis
62. Role of BAX in the apoptotic response to anticancer agents
63. L can confer a multidrug resistance phenotype
64. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells
65. Interleukin-3 induces the phosphorylation of a distinct fraction of bcl-2
66. Inactivation of Bcl-2 by phosphorylation
67. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
68. Bcl2 is the guardian of microtubule integrity
69. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
70. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: Combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and down-regulation of a phosphatase, PAC1
71. Expression and prognostic impact of ERK2, BCL-XL and PP2A in acute myelogenous leukemia (AML)
72. Mitochondria and programmed cell death: Back to the future
73. Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types